X @Bloomberg

US regulators approved GSK's blood cancer drug, a decision that will allow the company to bring the medicine back to the world’s biggest pharmaceutical market after questions about its effectiveness led to its withdrawal in 2022 https://t.co/X4muiEKfcL ...